HROW
HealthcareHarrow, Inc.
$54.80
+$4.89 (+9.80%)
Jan 5, 2026
Price History (1Y)
Analysis
Harrow, Inc. is a healthcare company specializing in drug manufacturers - specialty & generic. The company has a significant presence in its sector with a market capitalization of $2.03 billion and annual revenues exceeding $250 million. Financially, Harrow, Inc. has shown mixed results. Its net income is negative at -$4,988,000 (TTM), while EBITDA stands at $46.15 million. The company's gross margin is 74.6%, operating margin is 20.6%, and profit margin is -2.0%. Returns on equity and assets are -9.6% and 4.9%, respectively. Harrow, Inc.'s balance sheet indicates a debt-to-equity ratio of 539.79 and cash reserves of $77.46 million. Valuation metrics for Harrow, Inc. include a forward P/E ratio of 25.06 and a price to book ratio of 43.15. The company's revenue growth has been substantial at 45.4% (YoY), although earnings growth is not available due to N/A designation.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Visit website →Key Statistics
- Market Cap
- $2.03B
- P/E Ratio
- N/A
- 52-Week High
- $54.81
- 52-Week Low
- $20.85
- Avg Volume
- 653.28K
- Beta
- 0.02
Company Info
- Exchange
- NGM
- Country
- United States
- Employees
- 382